Skip to Content

Hematologic Cancer Trials

E1A11 Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Verus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Aims: The purpose of this study is to discover the best combination and duration of treatment for patients with myeloma using drugs that have been recently approved for myeloma.
Diagnosis: Myeloma
Principal investigator: David Grinblatt, MD
IRB Approval Number: EH16-306
Sponsor: ECOG-ACRIN
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

CareVive: The Roles of Education and Patient Engagement to Improve Symptom Management and the Quality of Life for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
Aims: The purpose of this study is to look at the effectiveness, acceptability and usability of web-based technology to report treatment side effects and receive care instructions.
Diagnosis: Chronic Lymphocytic Leukemia
Principal investigator: Alla Gimelfarb, MD
IRB Approval Number: EH17-244
Sponsor: Carevive
Contact: Interested patients should contact research nurse Susan Greve, RN at 847.503.1183
Open to Enrollment: Yes

A061202: A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib Vs. Pomalidomide and Dexamethasone for Patients wtih Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor-Based Therapy
Aims: The purpose of this study is to discover the best combination and duration of treatment for patients with myeloma using drugs that have been recently approved for myeloma.
Diagnosis: Myeloma
Principal investigator: David Grinblatt, MD
IRB Approval Number: EH17-069
Sponsor: Alliance
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

Celgene Connect MDS/AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
Aims: There are three main purposes of this study: 1. To use the information collected to help better understand patterns for diagnosis, treatment and outcomes, including disease progression and survival. 2. To use the information to help better understand patterns for the quality of life in patients newly diagnosed with Lower-Risk, Higher-Risk, or unknown risk MDS or AML. 3. To use results of this study to provide information to help better understand the effect different treatments have on a patient’s disease and on their quality of life.
Diagnosis: Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
Principal Investigator: Lynne Kaminer, MD
IRB Approval Number: EH13-390
Sponsor: Celgene
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

E1910: A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
Aims: The purpose of this study is to compare the effects, good and/or bad, the therapy blinatumomab has on your type of cancer (BCR/ABL negative ALL). This investigational drug will be added to what has traditionally been used to treat your specific sub-type of ALL. Studies are being done in ALL and other blood cancers with blinatumomab. It is hoped that blinatumomab will target your B-cell ALL and destroy these specific cells, but it has not yet been proven.
Diagnosis: BRCA/ABL negative Acute Lymphoblastic Leukemia (ALL)
Principal Investigator: Lynne Kaminer, MD 
IRB Approval Number: EH15-299
Sponsor: ECOG-ACRIN
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

UTX-TGR-205: A Phase 2b Randomized Study to Assess teh Efficacy and Safety of Combination of Ublituximab + TGR-1202 with our without Bendamustine and TGR-1202 alone in Patients wtih Previously Treated Non-Hodgkin's Lymphoma
Aims: The purpose of this study is to see how effective the combination of investigational drugs, ublituximab and umbraslisib are when given together compared to whn umbralisib is fiven alone.
Diagnosis: Non-Hodgkin's lymphoma
Principal Investigator: Lynne Kaminer, MD 
IRB Approval Number: EH17-290
Sponsor: TG Therapeutics
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

CIBMTR: Protocol for Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries 
Aims: The purpose of this study is to collect information on the collection of peripheral blood stem cells, transplant of stem cells, and the outcomes of patients who undergo peripheral blood stem cell transplant
Diagnosis: For patients undergoing a peripheral blood stem cell transplant
Principal Investigator: Lynne Kaminer, MD 
IRB Approval Number: EH15-249
Sponsor: National Marrow Donor Program
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

UC14-0899: Phase II Randomized Trial of Continuation of Post-Transplant Maintainence with Single-Agent Lenalidomide vs. Consolidation /Maintainence with Izaxomib-Lenalidomide-Dexamethasone in Patients with Residual Myeloma
Aims: The purpose of this study is to collect information on the combination of three treatments (Izaxomib-Lenalidomide and Dexamethasone)on the collection of peripheral blood stem cells, transplant of stem cells, and the outcomes of patients who undergo peripheral blood stem cell transplant
Diagnosis: For patients undergoing a peripheral blood stem cell transplant
Principal Investigator: David Grinblatt, MD 
IRB Approval Number: EH16-051
Sponsor: University of Chicago
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

UC13-1406: Prospective, Multi-Center Phase I/II Trial of Lenalidomide and Dose-Adjusted EPOCH-R in MYC-associated B-Cell Lymphoma
Aims: The purpose of this study is to about the combination of 6 drugs - lenalidomide, etoposide, vincristine, rituxumab, cyclophosphamide and doxorubicin.
Diagnosis: B-Cell Lymphona
Principal Investigator: Lynne Kaminer, MD 
IRB Approval Number: EH16-047
Sponsor: University of Chicago
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768 
Open to Enrollment: Yes

Astex SGI-110-07: A Phase 3, Multicenter, Randomized, Open-label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated Hypomethylating Agents
Aims: The purpose of this study is to see if AG-221 is safe and effective in treating AML compared to commonly used treatment options.
Diagnosis: Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia"
Principal Investigator: Lynne Kaminer, MD 
IRB Approval Number: EH17-102
Sponsor: Astex
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes